medigraphic.com
ISSN 1561-2945 (Print)

2020, Number 1

<< Back Next >>

Revista Cubana de Cirugía 2020; 59 (1)

Malignant pleural mesothelioma. Update on diagnosis and treatment

Gómez TG, Collado OJC

Language: Spanish
References: 39
Page: 1-14
PDF size: 293.00 Kb.


ABSTRACT

Introduction: Malignant Pleural Mesothelioma is a primary malignant tumor of the pleura, commonly associated with exposure to asbestos. It is considered a rare and very aggressive pathology.
Objective: Conduct a review of updated diagnostic and treatment criteria for malignant pleural mesothelioma.
Material and Methods: A bibliographic review was made through the search of information in sources available from the Cuban National Health Care Network and Portal (INFOMED), among them, databases such as SciELO, Pubmed / Medline, Cumed, Lilacs, as well as Google Scholar. Finally, a total of 39 references were selected for our study.
Conclusions: There are few references in the national literature related to the diagnosis, treatment and follow-up of patients with malignant pleural mesothelioma. The diagnosis combines the use of the clinical method, the imaging and histochemical studies. There is no standard treatment, being recommended an individualized approach that combines according to each case, surgery, chemo and radiotherapy. Future challenges include the development of new therapeutic alternatives.


REFERENCES

  1. Izquierdo-Sánchez V, Muñiz-Hernández S, Vázquez-Becerra H, Pacheco-Yepez J, Romero-Piña ME, Arrieta O, et al. Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft. Molecules. 2018 [acceso 11/01/2019];23:31-8. Disponible en: https://www.mdpi.com/1420-3049/23/12/3138

  2. Gonzáles Aste M, Coello Rodríguez R, Ortiz Muchotrigo N, Gonzáles Roca M, Báez Patiño AP, Sánchez Zavaleta C, et al. Mesotelioma pleural: experiencia durante 8 años y descripción de 20 casos en el Hospital Naval, Callao, Perú. Respirar. 2018;10(1):15-23.

  3. Gopar Nieto R, Cabello López A, Juárez Pérez CA, Haro García LC, Jiménez Ramírez C, Aguilar Madrid G, et al. Actualización sobre la epidemiología, fisiopatología, diagnóstico y tratamiento del mesotelioma maligno pleural. Rev Med Inst Mex Seguro Soc. 2016 [acceso 23/01/2019];54(6):770-6. Disponible en: http://www.medigraphic.com/pdfs/imss/im-2016/im166l.pdf

  4. Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a man-made epidemic. Eur Respir Rev. 2015;24(135):115–31.

  5. Demiroglu-Zergeroglu A, Ergene E, Ayvali N, Kuete V, Sivas H. Quercetin and Cisplatin combined treatment altered cell cycle and mitogen activated protein kinase expressions in malignant mesotelioma cells. BMC. Complementary and Alternative Medicine. 2016 [acceso 22/01/2019];16(281). Disponible en: https://bmccomplementalternmed.biomedcentral.com/track/pdf/10.1186/s12906-016-1267-x

  6. Ruiz CA, Gloazzo EA, AD Giacoia, Otero WG. Mesotelioma pleural maligno. Rev Argent Cirug. 2016 [acceso 22/01/2019];108(3):109-12. Disponible en: http://www.scielo.org.ar/pdf/racir/v108n3/v108n3a06.pdf

  7. Rodríguez Panadero F. Enfermedades de la pleura. En: Rozman Borsnart C, Cardellach López F (editors). Farreras-Rozman. Medicina Interna. 18va ed. Madrid: Elsevier. 2016 [acceso 12 /01/2019]:745-56. Disponible en: https://www.clinicalkey.es/#!/content/book/3s2.0-B9788490229965000806

  8. Armas Moredo K, García Rodríguez ME, Acosta Prieto S, Armas Pérez B. Mesotelioma pleural maligno en ocho pacientes y revisión del tema. Revista Cubana de Cirugía. 2016 [acceso 22/01/2019];55(4):340-7. Disponible en: http://scielo.sld.cu/pdf/cir/v55n4/cir09416.pdf

  9. Pérez Assef JJ, Nicolau Díaz OD, Morales Esteban G. Mesotelioma pleural con síndrome de osteólisis. MEDICIEGO. 2017 [acceso 12/02/2019];23(4):36-42. Disponible en: http://www.medigraphic.com/pdfs/mediciego/mdc-2017/mdc174f.pdf

  10. Gea-Izquierdo E. Mesotelioma pleural y exposición al amianto en España. Revista Cubana de Investigaciones Biomédicas. 2016 [acceso 22/01/2019];35(1):1-17. Disponible en: http://www.medigraphic.com/pdfs/revcubinvbio/cib-2016/cib161a.pdf

  11. Trotta A, Sousa Santana V, Alazraqui M. Mortalidad por mesotelioma en Argentina, 1980-2013. Salud Colectiva. 2017 [acceso 22/01/2019];13(1):35-44. Disponible en: https://www.scielosp.org/pdf/scol/2017.v13n1/35-44/es

  12. Ribak J, Lilis R, Suzuki Y, Penner L, Selikoff J. Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis and causes of death. Br J Ind Med. 1988;45:182-7.

  13. Rodríguez Panadero F. Diagnóstico y tratamiento del mesotelioma pleural maligno. Archivos de Bronconeumología. 2015 [acceso 12/1/2019];51(4):177-84. Disponible en: https://www.sciencedirect.com/science/article/pii/S0300289614002270

  14. Parreiras de Faria M, Teixeira da Costa F. Estudo de Caso: Mesotelioma de Pleura em mecânico-soldador. Laborare. 2018 [acceso 11/02/2019];I(1):119-28. Disponible en: https://trabalhodigno.org/laborare/index.php/laborare/article/view/2595-847x.2018-16/6

  15. Nuyts V, Nawrot T, Nemery B, Nackaerts K. Hotspots of malignant pleural mesothelioma in Western Europe. Transl Lung Cancer Res. 2018 [acceso 11/02/19];7(5):516-9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204417/pdf/tlcr-07-05-516.pdf

  16. Gilham C, Rake C, Burdett G, Nicholson AG, Davison L, Franchini A, et al. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med. 2016 [acceso 12/02/2019];73(5):290-99. Disponible en: https://spiral.imperial.ac.uk/bitstream/10044/1/31534/2/Occup%20Environ%20Med-2016Gilham-290-9.pdf

  17. Hasegawa S. Early mesothelioma revisited. Int J Clin Oncol. 2012;17:30-2.

  18. Comba P, D’Angelo M, Fazzo L, Magnani C, Marinaccio A, Mirabelli D, et al. Mesothelioma in Italy: the Casale Monferrato model to a national epidemiological surveillance system. Ann Ist Super Sanità. 2018 [acceso 22/01/2019];54(2):139-48. Disponible en: http://www.annali-iss.eu/article/view/720/409

  19. Accinelli RA, López LM. Asbesto: la epidemia silenciosa. Acta Médica Peruana. 2016 [acceso 22/01/2019];33:138–41. Disponible en: http://www.scielo.org.pe/scielo.php?pid=S1728-59172016000200008&script=sci_arttext

  20. Guzmán de Alba E. Temas Selectos de Oncología Torácica. Capítulo 10: Mesotelioma maligno y otros tumores primarios de la pleura. En: Ibarra Pérez C. (editor) Madrid: Edit. Elsevier; 2015.

  21. Moon EK, Litzky LA, Sterman DH. Malignant Mesothelioma and other primary pleural tumors. Fishman´s Pulmonary Diseases and Disorders: Mc Graw Hill Education. 2015;79.

  22. Fennell DA, Parmar A, Shamash J. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 2005 [acceso 22/01/2019];23:184–9. Disponible en: http://ascopubs.org/doi/full/10.1200/JCO.2005.07.050

  23. Gopar-Nieto R, Aguilar-Madrid G, Sotelo-Martínez L, Juárez-Pérez CA, Kelly-García J, Argote-Greene L, et al. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population. Arch Med Res. 2015 [acceso 22/01/2019];46:107-11. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0188440915000144

  24. Ferrante D, Mirabelli D, Tunesi S, Terracini B, Magnani C. Pleural mesothelioma and occupational and nonoccupational asbestos exposure: a case-control study with quantitative risk assessment. Occup Environ Med. 2016 [acceso 22/01/2019];73(3):147-53. Disponible en: https://oem.bmj.com/content/73/3/147.short

  25. Puchalski Kalinke L, Kalinke MA, Mansano Sarquis LM, Marcondes L, Halfeld T Mensi C. Uma proposta de criação de um sistema para monitoramento dos casos de mesotelioma maligno em Curitiba, Paraná, Brasil. Cad. Saúde Pública. 2018 [acceso 22/01/2019];34(9). Disponible en: https://www.scielosp.org/pdf/csp/2018.v34n9/e00171917/pt

  26. Zhoua H. Evaluation of the efficacy of the guideline on Reading CT images of malignant pleural mesotelioma with reference CT films for improving the proficiency of radiologists. EurJ of Radiol. 2013 [acceso 22/01/2019];82:169–76. Disponible en: https://www.sciencedirect.com/science/article/pii/S0720048X12002513

  27. Velarde Pedraza A, Barón Rodiz P, Sánchez Ortega F, Cárdenas Valencia C. ¡No nos olvidemos de la pleura! Claves para reconocer el mesotelioma pleural maligno. [Presentación Electrónica Educativa] Sociedad Española de Radiología Médica. 2018 [acceso 20/01/2019] Disponible en: http://www.piper.espacio-seram.com

  28. Van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: The standard of care and challenges for the future. Crit Rev Oncol Hematol. 2011;78:92-111.

  29. Koyuncu A, Koksal D, Ozmen O, Demirag F, Bayiz H, Aydogdu K, et al. Prognostic factors in malignant pleural mesothelioma: A retrospective study of 60 Turkish patients. J Cancer Res Ther. 2015;11(1):216–22.

  30. Metintas M, Ucgun I, Elbek O, Erginel S, Metintas S, Kolsuz M, et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol. 2002;41:1-9.

  31. Ray M, Kindler HL. Malignant Pleural Mesothelioma: An update on biomarkers and treatment. Chest. 2009;136:888-96.

  32. Najmi K, Khosravi A, Seifi S, Emami H, Chaibakhsh S, Radmand G, et al. Clinicopathologic and survival characteristics of malignat pleural mesothelioma registered in hospital cancer registry. Tanaffos. 2014;13(2):6–12.

  33. Ji J, Sundquist J, Sundquist K. Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study. European Respiratory Journal. 2016;48(3):873–9.

  34. Van Thiel E, van Meerbeeck JP. European guidelines for the management of malignant pleural mesothelioma. Pol Arch Med Wewn. 2010;120(12):503-10.

  35. Rodríguez Panadero F. Aspectos diagnósticos y terapéuticos en el mesotelioma pleural maligno. Rev Med Clin Condes. 2015 [acceso 12/01/2019];26(3):325-37. Disponible en: https://ac.els-cdn.com/S071686401500067X/1-s2.0-S071686401500067Xmain.pdf?_tid=98185772-c635-11e7-a87f00000aacb361&acdnat=1510332094_70095c87bec0b181187f6a3fc318bc4e

  36. Algranti E, Saito C, Carneiro A, Moreira B, Mendoça E, Bussacos M, et al. The next mesothelioma wave: Mortality trends and forecast to 2030 in Brazil. Cancer epidemiology. 2015;39(5):687-92.

  37. Muers MF, Stephens RJ, Fisher P. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008 [acceso 22/01/2019];371:1685–94. Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673608607278

  38. Soeberg MJ, Leigh J, Driscoll T, Armstrong B, Young JM, van Zandwijk N, et al. Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982–2009. Occup Environ Med. 2016 [acceso 22/01/2019];73(3):187–94. Disponible en: https://oem.bmj.com/content/73/3/187.abstract

  39. Dennis McCool F. Diseases of the diaphragm, chest wall, pleura, and mediastinum. Goldman-Cecil Medicine. 25ta ed. New York: Elsevier Saunders. 2016 [acceso 12/11/2016];2(37):627. Disponible en: https://www.clinicalkey.es/#!/content/book/3-s2.0-B9781455750177000994




2020     |     www.medigraphic.com